Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Tax Loss Selling

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Dec 08, 2022 12:52am

120 Views

Post# 35158180

RE:Tax Loss Selling

Yesterday the stock was up 6%, today it's down. Which day do you post? The stock is flat year over year at the moment and financials show no need for money. If you can handle the heat maybe sell and buy another company flat over the past 12 months, good luck finding that. Facebook, nope. Netflix, Nope. Walmart, nope.

honestly I hope you guys just sell so I don't have to read how you can run the company better than the 56% of insiders who may want a positive outcome.

show your offer and see what happens.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec